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Abstract 
Review on giant cell tumor of bone, with data on 
clinics, histopathology and genetics 
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A characteristic well-defined eccentric, lytic subchondral lesion involving the epiphysis and metaphysis. The 
borders are well defined and usually not sclerotic. Pathologic fracture is present in 5-10% of giant cell tumours. 
Dynamic MRI shows a fast uptake and a slow wash out of contrast. 
Classification 
Giant cell tumor of bone is a locally aggressive 
primary bone neoplasm. 
Clinics and pathology 
Disease 
Locally destructive, mono-ostotic tumoral lesion, 
typically presenting in the meta-epiphysis of long 
tubular bones with predilection for the knee region 
of skeletally mature patients (more than 95% of the 
patients is older than 25 years). Poly-ostotic lesions 
are exceptionally rare, counting for less than 1% of 
all cases. In these cases especially brown tumour of 
hyperparathyreoidism should be considered, which 
may look histologically identical. Although defined 
as a benign lesion, adjacent soft tissue invasion, 
angiovascular invasion and pulmonary metastases 
(1%) may occur. 
Phenotype / cell stem origin 
Primitive mesenchymal stromal cell. 
Embryonic origin 
Mesoderm. 
Etiology 
The exact origin is still unknown, but data obtained 
from ultrastructural analyses and cell cultures, as 
well as novel molecular data, suggest that the 
stromal cell, or mononuclear spindle cell, is 
neoplastic. The mononuclear rounded cells and the 
osteoclastic giant cells are seen as reactive. 
Therefore, some suggest that stromal cell tumour is 
a better name, because this fits more precisely the 
concept of the mononuclear spindled cell (stromal 
cell) as neoplastic. 
Epidemiology 
This tumour represents 8% of all primary and 
approximately 20% of benign primary bone 
tumours. Mostly affecting adults in the third, fourth 
and fifth decade of life (72%). It is very rarely seen 
under the age of 10 years (1,3%). There is a slight 
female predominance (male/female ratio: 
46,6%/53,4%). 
Clinics 
Pain of several weeks to months duration and a 
constantly expanding mass on X-ray, primary in the 
epiphysis, leading to cortex destruction, pathological 
fracture and soft tissue invasion. Finally ulceration 
of the skin occurs if not threatened. A pathological 
fracture could occasionally be the first sign of this 
tumour. 
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Mixture of three cellular components composites the tumour: tumoral spindle shaped mononuclear cells, reactive 
rounded mononuclear cells and diffusely scattered osteoclast type giant cells. Note that mitoses are strictly 
limited to the first cell type. 
Pathology 
A mixture of four components can be distinguished: 
S pindled-shaped and rounded mononuclear cells, 
Osteoclastic-type giant cells and small blood vessels.  
 
The spindle-shaped mononuclear cells are regarded 
as neoplastic. This cell type is thought to arise from 
the primitive mesenchymal stromal cell. 
Conventional mitotic figures are restricted to 
mononuclear cells. If atypical forms or strong 
nuclear atypia is noted, a secondary sarcomatous 
malignancy is almost always present. Secondary 
changes may be present like osteoid deposits, foci of 
fibrosis, collections of foamy cells or cystic 
degeneration. Secondary aneurysmal bone cyst 
formation is present in 6,5% of the cases. Mostly this 
is restricted to younger patients (median of 14 years). 
In the 2013 WHO classification, grading of 
histopathological features of GCTB is not 
considered predictive for clinical behaviour 
including risk for recurrent or metastatic disease. 
Originally, giant cell tumors of bone were 
histological graded into 3 grades according to Jaffe 
(1940) or into 4 grades (Netherlands Committee on 
Bone Tumours). 
Treatment 
Surgical intervention is the treatment of choice and 
therapeutic inhibition of osteoclast formation and 
activity with denosumab (RANK-RANKL inhibitor) 
provides another modality of treatment. Mostly a 
curettage followed by local adjuvant cryosurgery or 
phenol instillation is sufficient to eradicate this 
lesion and to save the joint. The use of 
polymethylmetacrylate for filling the cavity after 
curettage additively decreases the percentage of 
recurrences. An added advantage of using cement is 
that recurrences are detected sooner. Sometimes 'en 
bloc' resection is needed to be curative. Pulmonal 
metastases are treated by local excision. 
Evolution 
Non-treatment always leads to destruction of cortical 
bone, to soft tissue invasion and finally to ulceration 
of the skin. Local recurrences can occur following 
proper treatment, mostly indicating less radical 
initial resection. 
Prognosis 
Good, despite of recurrences and pulmonary 
metastases. In general much is depending on the 
surgical technique and expertise in combination with 
the histological grade of this tumour. Although 
pulmonary metastases may occur in rare cases, 
angiovascular invasion does not have any significant 
influence on its prognosis. The mortality rate due to 
giant cell tumour is about 4%. 
Genetics 
A specific driver mutation in the histone 3.3 gene 
H3F3A (p.Gly34) was recently identified in 
approximately 92% of giant cell tumours of bone. 
H3F3A mutation detection can be used as a 
diagnostic tool for the distinction of giant cell tumor 
of bone from other giant cell-containing tumors. A 
subset of the mutations can be easily detected using 
a G34W mutation specific antibody. 
Cytogenetics 
No recurrent chromosomal structural or numeric 
aberrations of importance have been detected yet. 
 
When confronted with a rearrangement, especially 
concerning 16q22 or 17p3, an associated aneurysmal 
bone cyst should be excluded. 
Cytogenetics Morphological 
The most frequent chromosomal anomaly is 
telomeric association. Comparing telomere length of 
giant cell tumours to this of leukocytes of the same 
patient, a reduction has been demonstrated. Most 
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commonly affected telomeres are 11p, 13p, 14p, 
15p, 19q, 20q and 21p. 
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